iSpecimen Reports 129% Year-Over-Year Increase in Third Quarter Revenue; Highlights Completed Orders for Federal Government and the Centers for Disease Control and Prevention (CDC)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iSpecimen (ISPC) reported a 129% year-over-year increase in third-quarter 2026 revenue and highlighted completed orders for government and government-affiliated research organizations. Revenue reached approximately $244,000, up from approximately $107,000 a year earlier, as specimen deliveries rose 169% to 752. Cost of revenue fell 55% to approximately $91,000. The company posted gross profit of approximately $153,000, compared with a gross loss of approximately $98,000 a year earlier. Its net loss narrowed to approximately $2.2 million from approximately $2.8 million.
Since 2020, iSpecimen has fulfilled 21 biospecimen orders across nine government and government-affiliated organizations, including projects with the Centers for Disease Control and Prevention. The company continued to receive public-sector inquiries, including requests in 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter 2026 revenue rose 129% year over year to approximately $244,000 from approximately $107,000
- Moderate pointThird-quarter gross profit reached approximately $153,000, compared with a gross loss of approximately $98,000 a year earlier
- Moderate pointThird-quarter specimen deliveries rose 169% to 752 from 280 a year earlier
- Minor pointThird-quarter cost of revenue fell 55% to approximately $91,000
- Minor pointAverage cost per specimen fell approximately 83% in the third quarter
- Minor pointCompleted government and government-affiliated orders totaled 21 across nine organizations since 2020, including the CDC
Negative
- Major pointThird-quarter net loss was approximately $2.2 million, narrower than approximately $2.8 million a year earlier
Details
Market Reaction – ISPC
On Nov 19, the day this news came out, the latest delayed price for ISPC is 1.01% below the previous close. Argus tracked a peak move of +16.6% during the session. Our momentum scanner has recorded 16 alerts for this stock so far that day. The latest delayed price is $0.53.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Revenue
- approximately $244,000; increase of 129%
- Third quarter 2026; approximately $107,000 in third quarter 2025
- Specimens delivered
- 752; increase of 169%
- Third quarter 2026, compared with 280 in the prior-year quarter
- Cost of revenue
- approximately $91,000; decrease of 55%
- Third quarter 2026
- Average cost per specimen
- reduction of approximately 83%
- Third quarter 2026
- Gross profit
- approximately $153,000
- Third quarter 2026; compared with a gross loss of approximately $98,000 in third quarter 2025
- Net loss
- approximately $2.2 million
- Third quarter 2026; compared with approximately $2.8 million in the prior-year period
- Completed biospecimen orders
- 21 orders across nine organizations
- Government and government-affiliated organizations since 2020
Key Terms
biospecimen medical
cerebrospinal fluid medical
formalin-fixed paraffin-embedded medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company has fulfilled 21 biospecimen orders for federal, state, and government-affiliated research organizations since 2020
Woburn, Massachusetts--(Newsfile Corp. - November 19, 2026) - iSpecimen Inc. (NASDAQ: ISPC), a global marketplace connecting researchers with biospecimens and clinical data, today reported a
Third Quarter 2026 Revenue Growth
Revenue for the third quarter ended September 30, 2026 was approximately
The Company also improved the economics of its fulfillment. Cost of revenue decreased
Experience Supporting Government Research
Since 2020, iSpecimen has fulfilled 21 biospecimen orders across nine government and government-affiliated organizations, including federal research agencies, national laboratories, and state public health organizations. This work includes previously announced projects with the Centers for Disease Control and Prevention (CDC), as well as additional engagements supporting a range of public-sector research initiatives.
The completed orders have involved at least seven categories of biospecimens, including whole blood, serum, cerebrospinal fluid (CSF), urine, saliva, swabs, and formalin-fixed paraffin-embedded (FFPE) tissue. Projects have supported research spanning infectious disease, public health, oncology, and other areas of biomedical investigation.
These engagements have required access to a range of specimen sources, including established inventories and collections coordinated to meet specific research requirements. Through its network of healthcare institutions, laboratories, and other collection partners, iSpecimen helps researchers identify and access human biospecimens for studies that may otherwise be difficult to source.
"Our third quarter results reflect renewed momentum in customer demand, with revenue more than doubling and specimen volume up
Continued Engagement and Future Opportunities
In addition to its completed orders, iSpecimen continues to receive inquiries and engage with government and public-sector organizations regarding new research needs. Recent discussions and requests, including activity in 2026, reflect continued interest in accessing diverse human biospecimens through iSpecimen's marketplace.
The Company sees continued opportunity to support government-funded and public-sector research by connecting researchers with its established supplier network and helping coordinate access to specimens across a broad range of collection settings.
About iSpecimen
iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate," "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.
Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Media Contact

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324745
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.